[go: up one dir, main page]

WO2000053205A1 - Utilisation de fleurs de houblon dans des traitements medicinaux - Google Patents

Utilisation de fleurs de houblon dans des traitements medicinaux Download PDF

Info

Publication number
WO2000053205A1
WO2000053205A1 PCT/NL2000/000074 NL0000074W WO0053205A1 WO 2000053205 A1 WO2000053205 A1 WO 2000053205A1 NL 0000074 W NL0000074 W NL 0000074W WO 0053205 A1 WO0053205 A1 WO 0053205A1
Authority
WO
WIPO (PCT)
Prior art keywords
substance
use according
furthermore contains
composition
unprocessed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2000/000074
Other languages
English (en)
Inventor
Danny Van Eijsselsteijn
Wouter Paulus Van Eeuwijk
Anita Anna Francisca Gertruda Dost
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP00904135A priority Critical patent/EP1161253A1/fr
Priority to AU25805/00A priority patent/AU2580500A/en
Publication of WO2000053205A1 publication Critical patent/WO2000053205A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3486—Humulus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8998—Hordeum (barley)

Definitions

  • the present invention relates to the use of unprocessed hop flowers for preparing a substance for suppressing and preventing the malignant growth of cancer cells, as well as to the use of unprocessed hop flowers for preparing a substance for treating viral and/or bacterial syndromes with a base of substantially natural products.
  • the present invention furthermore relates to tablets and to a method for preparing a composition with a liquid base, in dissolved and/or suspended form, and to the composition thus obtained, which is ingested orally.
  • Such an anti-cancer substance is known per se from JP- 52-145509-A, wherein hop flowers are dried at an elevated temperature for 5 - 15 hours until the moisture content has reached a value of 10 - 20%. The hop thus dried is then transferred to water and subjected to a temperature treatment at 60 - 65 ' C for 1 - 3 hours and at 90 - 100 ° C for 30 - 60 seconds.
  • European patent application No. 0 782 858 which was previously filed by the present applicant, and International patent application W098/35686 indeed relate to a substance which contains hop, but said substance is used for an essentially different purpose, viz. stimulating growth, unlike the present therapeutic effect, in particular suppressing and preventing the malignant growth of cancer cells as well as treating viral and/or bacterial syndromes, such as infection with the HIV virus, the herpes virus and Crohn's disease.
  • RU-2075313-C1 relates to a botanical composition for treating malignant cell growth, which composition comprises linseed, sunflower seeds, sesame seeds or soybean oil in an ethanol emulsion.
  • the use of hop is not known therefrom.
  • Substances with a vegetable base for suppressing and preventing the growth of malignant cancer cells are known per se and extensively described in US patents Nos. 5,792,503; 5,807,586 and 5,726,034.
  • the substances which are for example disclosed in US patent No. 5,726,034 are based on vegetable materials, in particular soybean.
  • Soybean is known to include genistein, daidzein and glycithein "families" of isoflavones.
  • the isoflavones present in vegetable proteins, such as soybeans are known to have medicinal value. It has been reported in particular that genistein and daidzein are capable of suppressing the growth of human cancer cells, such as breast cancer cells and prostate cancer cells.
  • the hitherto known nutrient sources for genistein are foodstuffs prepared from soybeans, such as soybean shoots, tofu (soya cheese) and tempeh. Tempeh is a fermented soybean product. Tofu is reported to contain 87 - 216 g of genistein. Beverages with a base of soybean, such as soya milk, contain much less genistein, and baby food prepared with soya milk only contains traces of genistein.
  • genistein like most isoflavones, exhibits a certain phytoestrogenic activity. After genistein has been introduced into the bloodstream, this substance as such, or via one of its conversion products, will exhibit a biologically active, hormone-like effect in the body.
  • Phytoestrogens such as genistein and daidzein are partially converted in the intestine into substances exhibiting a weak oestrogenic activity. These substances are assumed to be capable of occupying receptors. Thus tumours which depend on oestrogen for their growth are inhibited. Such tumours may form in the mammary gland, the prostate and the intestine.
  • the substance according to the present invention is produced as a powdery substance, from which tablets are made or which is dissolved and/or suspended in water by the user and subsequently ingested. It is also possible, of course, to market the present composition in dissolved/suspended condition.
  • the present invention thus relates to the use of unprocessed hop flowers for preparing a substance for suppressing and preventing the malignant growth of cancer cells.
  • the present invention relates to the use of unprocessed hop flowers for preparing a substance for the treatment of viral and/or bacterial syndromes.
  • unprocessed hop flowers is understood to mean that the hop flowers have not been subjected to temperature treatments, extraction treatments and the like, which treatments must be considered to be detrimental to the action of the active constituents that are present in hop flowers. Treatments such as grinding and screening are permissible, however, because such treatments do not have an adverse effect on the active constituents in hop flowers. Strobuli Humulus Lupulus is considered to be a suitable hop flower.
  • the effect of the substance for suppressing and preventing the malignant growth of cancer cells as well as for treating viral and/or bacterial syndromes can be advanced even further by adding to the substance one or more substances selected from the group of malt, wheat, barley, rye, maize and oat, in particular the nutrient or dietary fibres thereof.
  • the above-mentioned agricultural products in their most natural form, viz. in the form wherein the products such as malt, wheat, barley, rye, maize and oat are harvested, that is, the complete grain with the skin.
  • Said fibres restore the intestinal flora and thus contribute to supporting the body's own immune system.
  • linseed can be added to the present substance, wherein the use of linseed causes the amount of polyunsaturated fatty acids to increase, which thus has a favourable effect on the aforesaid novel and inventive therapeutic effects, in particular in the treatment of viral and/or bacterial syndromes as well as the suppression of malignant growth of cancer cells. Moreover, it has been established that the present substance has a preventative effect with regard to the growth of malignant cancer cells.
  • phosphorus is an essential constituent in the metabolism of fats and starch.
  • phosphorus is necessary for the assimilation of niacin, which niacin is water-soluble and which is often referred to as B3.
  • B3 is in particular important for the synthesis of sex hormones and of cortisone, thyroxin and insulin.
  • flavourings in particular flavourings which are known in connection with the preparation of instant pudding or the like having different tastes, for example. According to one embodiment, however, it is possible to form the present substance solely of unprocessed hop flowers as the active constituent as described before, although the taste will not be found to be pleasant or tasty, which embodiment will be explained in the examples hereinafter.
  • 1000 g of the present substance preferably contain 100 - 500 g of unprocessed hop flowers and 100 - 800 g of the sum of one or more of the ingredients malt, wheat, barley, maize, rey and oat, with the balance of the amount of 1000 g possibly consisting of linseed, sunflower seeds and/or flavourings.
  • 15 g) of the present substance mixed with about 100 ml of water are ingested after stirring. It is advisable to drink about 1.5 1 of water with a daily dose of 15 tablets.
  • a daily dose of this composition is taken, a reduction of the size of the malignant cancer cells can be observed after about 6 months already. After about 2 months the growth of the malignant cells will be stopped or in any case retarded. It has become apparent that when no malignant cells are developed any more, the present substance exhibits a preventive effect.
  • An amount of 200 g of unprocessed hop flowers is mixed with 20 g of an inert material, viz. starch, which functions as a carrier.
  • the mixture is transferred to 100 ml of water, after which the composition thus obtained is orally ingested in daily amounts corresponding to 2 g of active constituent, viz. unprocessed hop flowers.
  • the treatment was carried out for a period of four weeks, and after two weeks already a reduction of the size of the lumps in the breasts could be observed.
  • Example 2 300 g of unprocessed hop flowers are mixed with 100 g of maize, 100 g of barley, 100 g of malt, 100 g of linseed, 100 g of sunflower seeds and 100 g of wheat, with the cereals being fully composed cereals, that is, including the skin, to which 200 of rye are added. Then this mixture is further mixed with 80 g of oats and 20 g of starch, which functions as a carrier. Following homogeneous mixing of the materials, 5 g of the substance thus formed are suspended in 100 ml of water and stirred thoroughly. Then the composition is ingested. After ingestion of the substance once a day for one month, a preventive effect as regards the development of malignant cancer cells is already manifested, in particular in female breasts.
  • Example 2 The composition of example 2 was prepared, using 5 g of oats, 5 g of maize and 70 g of flavourings, viz. raspberry flavour instant pudding powder, instead of 80 g of oats, however.
  • the effect is similar to that observed in Example 2, but the substance is found to be tastier when ingested orally as a powder suspended in water.
  • 140 g of rye, 140 g of wheat, 140 g of malt, 140 g of oats, 140 g of maize and 100 g of barley are mixed, to which mixture 400 g of unprocessed hop flowers are added.
  • these tablets After being ingested in an amount of 10 tablets per day for a period of 60 days, these tablets provide an intended result, in particular with regard to the reduction of the malignant growth of cancer cells in female breasts. Comparative example.
  • composition according to example 1 was prepared, with this exception that hop treated in accordance with JP-52-145509-A was used.
  • Therapeutic treatment of malignant cancer cells with an amount of substance corresponding to 2 g of processed hop for a period of 10 weeks resulted in a barely noticeable reduction in the size of the lumps in the breasts of the test persons. This seems to indicate that the heating of the hop flowers has reduced the amount of active constituents to such a level that a non-active substance is obtained.
  • Example 5 The composition according to example 1 was used with patients infected with the HIV virus. The amount of virus-infected cells decreased considerably within 6 weeks after the daily ingestion of 8 - 11 g of active constituent was started.
  • composition according to example 1 was used, with this exception that no oats, rye or starch were added.
  • the composition thus prepared was administered orally to patient's having Crohn's disease, using the same dose as in example 2. After a period of 2 weeks already a significant alleviation of the test persons' symptoms was observed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne l'utilisation de fleurs de houblon dans la préparation d'une substance destinée à bloquer et à prévenir la croissance maligne de cellules cancéreuses ainsi que l'utilisation de fleurs de houblon dans la préparation d'une substance destinée au traitement de syndromes viraux et/ou bactériens sur la base de produits sensiblement naturels. La présente invention concerne en outre un procédé pour préparer une composition sur une base liquide, c'est-à-dire sous la forme d'une solution et/ou d'une suspension, la présente substance étant mélangée à de l'eau.
PCT/NL2000/000074 1999-03-11 2000-02-04 Utilisation de fleurs de houblon dans des traitements medicinaux Ceased WO2000053205A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00904135A EP1161253A1 (fr) 1999-03-11 2000-02-04 Utilisation de fleurs de houblon dans des traitements medicinaux
AU25805/00A AU2580500A (en) 1999-03-11 2000-02-04 Use of hop flowers for medicinal treatments

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1011529A NL1011529C2 (nl) 1999-03-11 1999-03-11 Middel ter onderdrukking en preventie van de kwaadaardige groei van kankercellen.
NL1011529 1999-03-11

Publications (1)

Publication Number Publication Date
WO2000053205A1 true WO2000053205A1 (fr) 2000-09-14

Family

ID=19768819

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2000/000074 Ceased WO2000053205A1 (fr) 1999-03-11 2000-02-04 Utilisation de fleurs de houblon dans des traitements medicinaux

Country Status (4)

Country Link
EP (1) EP1161253A1 (fr)
AU (1) AU2580500A (fr)
NL (1) NL1011529C2 (fr)
WO (1) WO2000053205A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1018170C2 (nl) 2001-04-25 2002-10-29 Whiplash Preventie Systems Hol Stoel met ten opzichte van de zitting verplaatsbare rugleuning en daarin toe te passen verplaatsingsinrichting.
RU2281782C2 (ru) * 2000-03-24 2006-08-20 ДЕ ВИЛ Адриан Эманюэль Хендрикус Анна Мария ВАН Применение хмеля и орнитина в косметике
WO2009063221A3 (fr) * 2007-11-13 2009-07-02 Biotec Pharmacon Asa Procédés de traitement ou de prévention de maladies inflammatoires du tractus intestinal

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52145509A (en) * 1976-05-27 1977-12-03 Tokutarou Matsui Antitumor agent
RU2075313C1 (ru) * 1993-12-16 1997-03-20 Владимир Сергеевич Павличенко Средство и способ для лечения больных злокачественной опухолью по павличенко в.с.
EP0782858A1 (fr) * 1995-11-17 1997-07-09 van Eijsselsteijn, Danny Substance favorisant la croissance
WO1998035686A1 (fr) * 1997-01-23 1998-08-20 Danny Van Eijsselsteijn Substance stimulant la croissance

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52145509A (en) * 1976-05-27 1977-12-03 Tokutarou Matsui Antitumor agent
RU2075313C1 (ru) * 1993-12-16 1997-03-20 Владимир Сергеевич Павличенко Средство и способ для лечения больных злокачественной опухолью по павличенко в.с.
EP0782858A1 (fr) * 1995-11-17 1997-07-09 van Eijsselsteijn, Danny Substance favorisant la croissance
WO1998035686A1 (fr) * 1997-01-23 1998-08-20 Danny Van Eijsselsteijn Substance stimulant la croissance

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 197803, Derwent World Patents Index; Class B04, AN 1978-05666A, XP002120184 *
DATABASE WPI Section Ch Week 199742, Derwent World Patents Index; Class B04, AN 1997-455743, XP002120183 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2281782C2 (ru) * 2000-03-24 2006-08-20 ДЕ ВИЛ Адриан Эманюэль Хендрикус Анна Мария ВАН Применение хмеля и орнитина в косметике
NL1018170C2 (nl) 2001-04-25 2002-10-29 Whiplash Preventie Systems Hol Stoel met ten opzichte van de zitting verplaatsbare rugleuning en daarin toe te passen verplaatsingsinrichting.
WO2002085664A2 (fr) 2001-04-25 2002-10-31 Whiplash Preventie Systems Holding N.V. Siege a dossier mobile sur l'assise et dispositif mecanique a cet effet
WO2009063221A3 (fr) * 2007-11-13 2009-07-02 Biotec Pharmacon Asa Procédés de traitement ou de prévention de maladies inflammatoires du tractus intestinal

Also Published As

Publication number Publication date
AU2580500A (en) 2000-09-28
NL1011529C2 (nl) 2000-09-12
EP1161253A1 (fr) 2001-12-12

Similar Documents

Publication Publication Date Title
EP0282002B1 (fr) Compositions d'orges et de bot orties comme adjonction alimentaire ou de préparation pharmaceutique dans les soins de santé humaine
CN103355556A (zh) 一种玉米型断奶仔猪配合饲料及其制备方法
JP2007535576A (ja) 迅速な体重減少を促進し、カロリーを燃焼させ、熱発生を増大させ、エネルギー代謝を補助し、且つ／または食欲を抑制する栄養組成物
EP0656786A1 (fr) Complements benefiques pour la sante, contenant des phyto- strogenes, des analogues ou des metabolites de ceux-ci
CN110447902B (zh) 一种具有减肥功效的组合物
CN102144748A (zh) 具有排毒护肝养颜功能的五色面制食品
CN102178183A (zh) 一种五豆综合营养食品
CN108771219A (zh) 食叶草植物蛋白营养含片及其制备方法
CN104479946A (zh) 黄秋葵、菌、藻植物组合物制作营养露酒的方法
KR19990084077A (ko) 비만개선을 위한 저당식 기능성 식품
DK169714B1 (da) Olieholdig præparation og fremgangsmåde til fremstilling heraf
CN111771970A (zh) 有助于养胃、护胃的组合物及其制备方法
CN110638038A (zh) 一种用于控制高血糖的医学配方营养代餐粉及其制备方法
CN109170916A (zh) 一种强身健体食品组合物及其制备方法
WO2000053205A1 (fr) Utilisation de fleurs de houblon dans des traitements medicinaux
JP2001199892A (ja) アミグダリン含有物の抗腫瘍活性強化方法、抗腫瘍活性強化アミグダリン含有物を含む組成物、アミグダリン含有物処理の抗腫瘍有効性評価方法、およびアミグダリン含有物の抗腫瘍有効性評価方法
JP2003342188A (ja) 抗ガン剤
EP1413208A1 (fr) Aliment diététique et agent antitumoral
CN101933968A (zh) 一种具有抗氧化、延缓衰老功能的药物组合物及其制备方法
CN111528386B (zh) 一种山楂纳豆固体饮料及其制备方法
KR20000018977A (ko) 동아 녹즙 및 그 잔사를 사용하여 제조된 체중 및 혈당 조절용식품조성물 및 그 제조방법
CN107136490A (zh) 一种肽虫草保健品
CN109329897A (zh) 一种用于癌症的辅助治疗食品组合物及其制备方法
CN118453705B (zh) 一种用于减肥的药物组合物及其应用和制剂
JP2003171306A (ja) 生理活性組成物及びその製造方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000904135

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000904135

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000904135

Country of ref document: EP